Vedolizumab

Maternal vedolizumab injections produce low levels in breastmilk and do not appear to adversely affect the nursing infant. Because vedolizumab is a large protein molecule with a molecular weight of about 147,000 Da, it is likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Vedolizumab does not affect SIgA, SIgM levels in milk in women with inflammatory bowel disease. Waiting for at least 2 weeks postpartum to resume therapy suspended during pregnancy may minimize transfer to the infant.[2] However, in infants of mothers who received vedolizumab during late pregnancy, continued use while breastfeeding did not prolong vedolizumab elimination by the infant. Most experts and guidelines consider vedolizumab to be probably acceptable during nursing.[3-7]